{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 40 of 169', '7 Trial design', '7.1 Overall trial design', 'Overview', 'This is a phase 3 randomised, double-blinded, placebo-controlled trial in adult subjects with', 'moderate-to-severe AD. The trial will consist of a screening period of 2 to 6 weeks', '(Weeks -6/-2 to 0), an initial treatment period of 16 weeks (Weeks 0 to 16) and a maintenance', 'treatment period of 36 weeks (Weeks 16 to 52). The primary endpoint is assessed at Week 16,', 'and the final efficacy assessment will be conducted at Week 52. A 14-week off-treatment', 'follow-up period for the assessment of safety is also included (Weeks 52 to 66). Subjects not', 'achieving a clinical response at Week 16 as well as those who meet certain criteria during', 'maintenance treatment will be transferred to open-label tralokinumab 300 mg Q2W treatment', 'with optional use of TCS up to Week 52. An overview of the different parts of the trial is', 'provided in Panel 1 and Panel 9.', 'Screening period (Week -6 to Week 0)', 'The screening period has a minimum duration of 2 weeks and a maximum duration of', '6 weeks and includes 1 or 2 screening visits. The exact duration of the screening period', 'depends on the washout period defined by the exclusion criteria (Section 8.3). If a washout is', 'not required, screening will be reduced to 2 weeks and only requires 1 visit (Week -2; visit 2),', 'i.e., the 2 screening visits will be merged. Similarly, if only a 2-week wash-out is required,', 'screening visits 1 and 2 will be combined (Week -2; visit 2). Eligibility will be assessed at the', '(first) screening visit and on Day 0 prior to randomisation.', 'All subjects will attend a screening visit 14 days before baseline (Week -2; visit 2) where they', 'will receive electronic diary (eDiary) training and start the eDiary. Data entered in the eDiary', 'during the 2 weeks before randomisation will be used to calculate baseline values of the', 'patient-reported outcomes (PROs).', 'All subjects will use an emollient twice daily (or more, as needed) for at least 14 days before', 'randomisation and will continue this treatment throughout the trial. Subjects will initiate', 'emollient treatment no later than the Week -2 visit.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 41 of 169', 'Initial treatment period (Week 0 to Week 16)', 'Following the screening period, approximately 780 subjects will be randomised 3:1 to one of', 'the following groups stratified by region and disease severity (IGA of 3 or 4)', 'Tralokinumab 600 mg (4 mL) at Day 0 (hereinafter \"baseline\"), then 300 mg', '(2 mL) Q2W.', 'Placebo (4 mL) at baseline, then placebo (2 mL) Q2W.', 'Maintenance treatment period (Week 16 to Week 52)', 'Subjects achieving a clinical response at Week 16 will continue into maintenance treatment', 'that will continue until Week 52.', 'Clinical response is defined as IGA of 0 or 1, or at least 75% reduction in EASI score from', 'baseline (EASI75).', 'Subjects randomised to tralokinumab in the initial treatment period will be re-randomised', '2:2:1 to one of the following Q2W maintenance regimens stratified by region and IGA', 'response at Week 16 (IGA 0/1 or IGA>1):', \"Tralokinumab 300 mg (2 mL) (tralokinumab Q2W').\", 'Alternating dose administrations tralokinumab 300 mg (2 mL) and placebo (2 mL)', \"(tralokinumab Q4W').\", 'Placebo (2 mL).', 'Subjects randomised to placebo in the initial treatment period who achieve a clinical response', 'at Week 16, defined by IGA of 0 or 1, or EASI75 will continue to receive placebo Q2W in the', 'maintenance treatment period.', 'Transfer to open-label treatment', 'Subjects will be transferred from maintenance treatment to open-label treatment', '(tralokinumab 300 mg Q2W with optional use of TCS) if they meet the criteria listed below.', 'Transfer to open-label may occur at any visit while the subject is in the maintenance treatment', 'period but no earlier than Week 22.', 'Subjects with IGA=0 at Week 16:', 'IGA of at least 2 and not achieving EASI75 over at least a 4-week period (i.e., over', '3 consecutive visits).', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}